Streetbeat News

NYXH

Nyxoah S.A.

https://www.nyxoah.com

Industry

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Open

10.44

Mkt cap

365M

Volume

71K

High

10.63

P/E Ratio

-5.38

52-wk high

16.08

Low

10.35

Div yield

N/A

52-wk low

6.76

Nyxoah has announced a partnership with ResMed in Germany to create a continuum of care in the German obstructive sleep apnea market.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 8:32 pm

Cantor Fitzgerald analyst Steven Halper has reiterated an Overweight rating on Nyxoah (NASDAQ:NYXH) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 3:48 pm

Cantor Fitzgerald analyst Steven Halper has reiterated an Overweight rating on Nyxoah (NASDAQ:NYXH) and maintained a price target of $11.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 3:41 pm

Piper Sandler analyst Adam Maeder maintains an Overweight rating on Nyxoah (NASDAQ:NYXH) but lowers the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 8:21 pm

Cantor Fitzgerald analyst Steven Halper has maintained an Overweight rating on Nyxoah (NASDAQ:NYXH) but lowered the price target from $12 to $11.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 5:51 pm

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Nyxoah (NASDAQ:NYXH) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:16 am

Nyxoah (NASDAQ:NYXH) reported Q2 losses of $(0.49) per share, missing the analyst consensus estimate of $(0.45) by 8.89%. This is a 133.33% increase in losses from the same period last year. However, the company's quarterly sales of $1.21 million beat the analyst consensus estimate of $1.08 million by 11.76%, marking a 21.12% increase over sales from the same period last year.

Portfolio Pulse from mahesh@benzinga.com

August 08, 2023 | 9:37 pm

Over the last quarter, Nyxoah (NASDAQ:NYXH) has received four analyst ratings, all of which were either bullish or somewhat bullish. The average 12-month price target for the company is $13.5, representing an 11.94% decrease from the previous average price target of $15.33.

Portfolio Pulse from Benzinga Insights

July 31, 2023 | 9:23 pm

HC Wainwright & Co. analyst Edward White has initiated coverage on Nyxoah (NASDAQ:NYXH) with a Buy rating and a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:12 am

In the last quarter, 4 analysts have rated Nyxoah (NASDAQ:NYXH) with 2 bullish and 2 somewhat bullish ratings. The average price target is $13.75, representing an upside from the current price of $7.675. This is a 15.38% decrease from the previous average price target of $16.25.

Portfolio Pulse from Benzinga Insights

May 18, 2023 | 1:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.